Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $20.83.

ALT has been the topic of several recent analyst reports. Stifel Nicolaus began coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and set a $12.00 price target on shares of Altimmune in a report on Tuesday, March 18th. Finally, William Blair restated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th.

Altimmune Stock Performance

Shares of ALT traded down $0.28 during mid-day trading on Friday, reaching $5.62. The company had a trading volume of 1,216,229 shares, compared to its average volume of 2,985,976. The company has a market capitalization of $432.43 million, a price-to-earnings ratio of -3.62 and a beta of 0.87. The firm has a 50-day moving average price of $6.31 and a 200 day moving average price of $7.08. Altimmune has a 52 week low of $5.14 and a 52 week high of $11.16.

Remove Ads

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, research analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Buying and Selling at Altimmune

In other news, CFO Gregory L. Weaver purchased 10,000 shares of the business's stock in a transaction on Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now directly owns 10,000 shares in the company, valued at $52,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On Altimmune

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Larson Financial Group LLC purchased a new stake in Altimmune during the third quarter valued at approximately $31,000. SBI Securities Co. Ltd. purchased a new stake in shares of Altimmune in the 4th quarter worth $45,000. Virtus ETF Advisers LLC bought a new position in Altimmune in the 4th quarter worth $60,000. Cullen Frost Bankers Inc. purchased a new position in Altimmune during the fourth quarter valued at $72,000. Finally, 180 Wealth Advisors LLC bought a new stake in Altimmune during the fourth quarter valued at about $78,000. Hedge funds and other institutional investors own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.